Gadoxetic Acid

drug
On this page

Also known as Acide gadoxetiqueAcido gadoxeticoGadoxetate

Summary

Gadoxetic Acid (CHEMBL2221312) is an approved small molecule (ATC V08CA10).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: V08CA10
  • Clinical trials: 2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2221312
NameGadoxetic Acid
TypeSmall molecule
Max phase4
ATCV08CA10

Also known as: Acide gadoxetique, Acido gadoxetico, Gadoxetate, Gadoxetic acid, GADOXETIC ACID

Parent form; salt/anhydrous children: CHEMBL2103740

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 2.

Phase distribution

PhaseTrials
PHASE41
Not specified1

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01575574PHASE4COMPLETEDMagnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis
NCT02395991Not specifiedCOMPLETEDEvaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.